Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.
In a recent interview, Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed notable advancements in the treatment of multiple myeloma. He also expressed excitement about the potential of cell therapies and bispecific antibodies in myeloma treatment. Systems need to balance the cost-effectiveness with the clinical effectiveness of newer treatments like chimeric antigen receptor T-cell therapies (CAR T) and bispecific monoclonal antibodies, he explained.
Sanchez participated in a panel discussion on best practices in multiple myeloma care at a recent Institute for Value-Based Medicine® event in Chicago.
This transcript has been lightly edited for clarity.
Transcript
What are some of the most notable advancements you’ve seen in the treatment of multiple myeloma in recent years, and how have they impacted patient outcomes?
We've seen great achievements. I think one of the most important ones has been the addition of the anti–CD-38 monoclonal antibodies, and adding them to the backbone of RBD [lenalidomide (Revlimid), bortezomib, and dexamethasone] or KRD [carfilzomib (Kyprolis), lenalidomide, and dexamethason] previous treatments. With those [as] induction chemotherapy, we've had the greatest responses that we've ever seen in multiple myeloma. So I think that has certainly affected the outcome in terms of response rates, progression-free survival, and hopefully overall survival in the future. We're excited to see that. Additionally, cell therapies and bispecifics are very interesting therapies. So we're excited to see myeloma [treatments] moving there as well.
How do you approach the challenge of balancing cost-effectiveness with clinical effectiveness when incorporating novel therapies like CAR T and bispecific antibodies into multiple myeloma care?
That's a great question. [With] all of our therapies, the better they get, the more expensive they get. So that's a challenge, and it's a challenge for our system. For the most part, so far, I think we always put efficacy first. In that way, I think using CAR Ts are the most efficacious treatments, and then bipecifics. But again, I think that's the challenge we all have. I work where we see a patient population who is insured by Medicare or Medicaid, so we are more limited than other institutions in the state, so we have to be cognizant of that or of what treatments we're going to give. But I think efficacy goes first from our standpoint.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More